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Objectives: Foot ulceration is a major cause of disability in diabetic patients. 
Disability of patients with diabetic foot ulceration (DFS – Diabetic Foot Syndrome) 
concerns not only patients themselves, but also the informal caregivers, mainly 
their close relatives. The aim of this study was to estimate lost productivity in 
a population of family caregivers of patients with diabetic foot ulceration in 
Poland. MethOds: A survey among 189 patients with DFS (treated in ambulatory 
care) and their families was conducted. To assess the impact of diabetic ulceration 
on productivity of caregivers to DFS patients the modified questionnaire WPAI-CG 
was used. The PEDIS scale was used to classify severity of ulceration. Results: A 
total of 116 out of 189 questionnaires were collected, and data on 93 responders 
(25 males) were included in the analysis (23 questionnaires were returned empty 
or concluded that informal care is not provided to DFS patients). Fifty-two (13 
males) out of 93 caregivers were employed at the time of the survey. Mean age 
of the population of caregivers was 45.9±11.2 years. Most were close relatives of 
DFS patients (58% spouses, 27% children). Almost half caregivers were employed 
in private sector (46%). Most had higher (50%) or secondary (48%) education. The 
average weekly work time declared was 40.4±13.1 hours. Approximately 70% of 
caregivers were urban population. The average percentage of work time missed 
and the percentage of working impairment while working due to informal care 
of DFS patients were estimated at 11.9% and 25.0%, respectively. The percentage 
of overall work impairment due to informal care of DFS patients was 32.2%. This 
amounts to weekly average time of the absence of 13.0 hours. cOnclusiOns: 
The lost productivity due to informal care on DFS patients is substantial and may 
have important implications for the economy.
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insuLin in Patients with t2Dm in the norwegian setting in one year
Levorsen A.1, Jespersen S.1, Chou E.2
1Sanofi, Lysaker, Norway, 2Sanofi, Bridgewater, NJ, USA
Objectives: GLP-1 agonists in combination with basal insulin (BI) have demon-
strated additional improvement of glycemic control in uncontrolled T2DM patients 
in clinical trials. It is therefore important to assess the real-world utilisation of 
GLP-1 agonists in combination with BI in T2DM patients. MethOds: Retrospective 
cohort analysis (2010 to 2012) to assess GLP-1 agonist utilisation in T2DM patients 
based on the Norwegian Institute of Public Health Prescription Database (NorPD). 
Both ICPC= T90 and ICD-10= E11 were applied to identify T2DM patients. Patients 
who had ≥ 2 GLP-1 dispensed within 6-month in Year-2011, with 1-year pre-Base-
line/post- Follow-up GLP-1 initiation were included in the analysis. Baseline anti-
diabetic drug use and combination use of GLP-1 and BI at Follow-up were also 
assessed. Results: Of the 1,500 GLP-1 initiators identified (mean age= 57; 52% 
male) at Baseline, 77% were on OADs, 19% on BI, 2% on prandial insulin (no BI) 
and 2% on other/no anti-diabetic drug. During 1-year Follow-up of GLP-1 adding 
on OADs patient population, 56% used GLP-1 continuously including 50% who 
used GLP-1 alone and 6% added BI. In total, 15% had either combined with or 
switched to BI, 4 months after the first GLP-1 was dispensed. Of those GLP-adding 
on BI patient population, 53% continuously used GLP-1 including 26% had both 
GLP-1 and BI dispensed throughout the Follow-up. About 52% had either BI inter-
rupted or discontinued approximately 2 months after the first GLP-1 was dis-
pensed. In total, 27% had insulin bolus dispensed; of which 58% either interrupted 
or discontinued GLP-1. cOnclusiOns: About 1/3 of GLP-1 initiators were in com-
bination with BI. In BI treated T2DM patients > 25% remained on both GLP-1 and 
BI, while another > 25% required treatment augmentation or switched to bolus. 
The data suggests an unmet treatment need, particularly in T2DM patients treated 
with BI.
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Objectives: To provide a comprehensive and coherent reference document of 
published cost data for diabetic complications in France, Germany, Italy and Spain 
for use in economic diabetes modeling. MethOds: A search for published cost of 
diabetes complications data from a health care payer perspective was performed 
on government websites, in peer-reviewed journals and local cost experts. All costs 
were inflated to 2013 Euros (€ ). Results: First year costs of myocardial infarction 
varied between € 3,041 in France and € 9,690 in Germany. Heart failure costs were 
similar across countries: € 3,104 in France; € 2,791 in Germany; € 4,000 in Italy and 
€ 3,316 in Spain. Costs of non-fatal stroke were higher in Germany (€ 16,441) than in 
other countries (Spain € 8,016; Italy € 6,073; France € 5,447). Everywhere, the cost of 
haemodialysis was higher than peritoneal dialysis € 35,972 versus € 21,255 in Spain, 
€ 21,552 versus € 18,485 in Italy, € 34,290 versus € 34,069 in Germany € 71,683 versus 
€ 48,752 in France. Renal transplant cost was estimated to € 84,114 in France, € 34,858 
in Germany, € 38,528 in Italy and € 26,618 in Spain. The cost of a major hypoglycemia 
requiring medical care was € 4,275 in Spain, € 2,561 in Germany, € 1,391 in Italy and 
€ 1,165 in France. Neuropathy complication costs varied widely: € 3,808 (France); 
€ 16,762 (Germany); € 4,290 (Italy); and € 5,330 (Spain) for foot ulcers and € 6,056 (Italy); 
€ 7,754 (Germany); € 9,578 (France); and € 12,118 (Spain) for lower-extremity ampu-
tation. cOnclusiOns: This study provides a coherent set of costs for diabetes 
complications in four European countries. Due to the differences in health care 
Objectives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated efficacious blood glucose control, 
with less hypoglycaemic events, and with an option for flexibility in dose time, 
compared with insulin glargine (IGlar). The objective was to assess the cost-
effectiveness of IDeg in Belgium, compared with IGlar. The analysis focused on 
patients in three treatment regimens: T1DM, T2DM treated with basal insulin in 
combination with oral anti-diabetics (BOT) and T2DM treated with basal-bolus 
(BB). MethOds: A one-year cost-utility model driven by differences in hypogly-
caemia was used. Published dis-utilities for hypoglycaemic events were multiplied 
by the rate of hypoglycaemia to calculate quality-adjusted life years (QALYs). Costs 
and utilities were also calculated for potential use of less blood glucose test strips. 
A utility gain was attributed to the additional benefit of dosing flexibility. Unit 
costs pertained to public tariffs and reflected the payer perspective in Belgium. 
Baseline incidence rates of hypoglycaemic events and related resource utilization 
pertained to a Belgian patient-reported outcomes study. Hospitalization costs 
following severe hypoglycaemia were estimated using the IMS Hospital Disease 
Database. Results: IDeg was associated with an incremental cost-effectiveness 
ratio of 14,677€ /QALY in T1DM, 4,976€ /QALY in T2DM BOT, and 12,930€ /QALY in 
T2DM BB. Univariate and probabilistic sensitivity analyses confirmed robust 
results. Results were most sensitive to variations in number of IGlar doses per 
day, and number of glucose-monitoring tests. At a willingness to pay threshold of 
30,000€ /QALY, IDeg would be cost-effective in 54%, 100% and 93% of the cases in the 
T1DM, T2DM BOT or T2DM BB treatment regimens respectively. cOnclusiOns: 
These analyses demonstrate that IDeg is cost-effective in Belgium, when used 
in patients with T1DM and T2DM currently treated with long-acting insulin ana-
logues.
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Objectives: The analysis goal is to determine the cost-effectiveness of liraglutide 
as add-on to metformin in for patients with type 2 diabetes in condition of the 
Russian health care system. Total medical expenses and effectiveness in terms of 
QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combina-
tion with metformin, and metformin monotherapy. MethOds: Data were sourced 
from a clinical trial comparing liraglutide vs. glimepiride (in combination with 
metformin), and a clinical trial comparing liraglutide vs. rosiglitazone (as add-on to 
metformin). From them data on clinical effectiveness in form of impact on HbA1(c), 
body mass index and blood pressure are extracted. Utility values are mostly taken 
from the UK Prospective Diabetes Studies supplemented with other published 
sources. The analysis is conducted from the perspective of the Russian health care 
system. Respectively the cost of the following resources is accounted: comparing 
of alternatives, concomitant pharmacotherapy, cost of medical manipulation, cost 
of ambulatory visits. Both future costs and clinical benefits are discounted at 3 
percent. Sensitivity analysis is performed. Results of this analysis are shown in the 
incremental cost-utility rate (ICUR). Results: The data of the analysis illustrates 
that liraglutide therapy for type 2 diabetes patients provides a significant health 
improvement from the perspective of quality adjusted life-years. Simultaneously 
liraglutide demonstrates better cost-effectiveness than the compared alternatives. 
The ICUR index of 1.2 mg liraglutide in combination with metformin equal to 1 
348368 rub, 1 161874 rub and 537331 rub for QALY in comparison with metformin 
monotherapy, glimepiride and rosiglitazone, both in combination with metformin, 
respectively. cOnclusiOns: Liraglutide has turned to be cost-effective therapeu-
tic alternative for treatment of type 2 diabetes in adult patients in conditions of 
Russian health care system over a 10-year time horizon.
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Objectives: To evaluate the long-term cost effectiveness of sitagliptin com-
pared to glimepiride and acarbose in the treatment of type 2 diabetes mellitus in 
China. MethOds: Sitagliptin, as add-on therapy to metformin, was compared to 
glimepiride and acarbose, and as monotherapy was also compared to acarbose. 
The validated UKPDS Outcomes Model was used to estimate the direct medical 
costs and outcomes (life years and QALYs gained). The demographic characteris-
tics and clinical data were taken from published literature. The quality of life data 
was obtained from published literature and re-confirmed through a questionnaire 
survey from a clinical expert panel of 20 diabetes specialists. The cost of drugs 
was calculated based on government guidance price or actual market price. The 
annual cost of complications was estimated based on expert opinions. Patients’ 
outcomes were modeled for 40 years and incremental cost-effectiveness ratios 
were calculated. Both future costs and clinical benefits were discounted at 3 
percent. A probabilistic sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. Results: The results showed that, 
compared to the treatment of glimepiride and acarbose plus metformin therapy, 
the add-on of sitagliptin provided a gain of 0.02 and 0.95 QALYs per patient, and 
the incremental cost-effectiveness ratios were USD 9,470 and USD 399, respec-
tively. The results also showed that compared to acarbose monotherapy (100mg 
t.i.d and 200mg t.i.d), the sitagliptin monotherapy (100mg/d and 200mg/d) was 
dominant, with higher QALYs (0.58 and 0.92) and years of life (0.72 and 1.23) 
gained and lower cost (USD 90 and USD 185). cOnclusiOns: According to the 
China’s GDP per capita in 2011 (USD 5,674), the results demonstrate that sitag-
liptin is more cost-effective than glimepiride and acarbose in the treatment of 
diabetes mellitus in China.
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sulphonylureas were less likely to be persistent than those initiated on metformin 
(OR= 0.50; 95%CI= 0.45 to 0.54; p< .0001). cOnclusiOns: Persistence amongst newly 
treated T2DM patients appears to be low. Type of OHM, age and scheme were all 
significantly associated with persistence. Prescribers should pay particular atten-
tion to newly treated patients covered under the GMS scheme, at the extremes of 
age and those initiated on sulphonylureas.
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Objectives: The impact of memory problems (MPs) on patient’s insulin taking 
behavior, functioning, well-being and diabetes management is not well under-
stood. MethOds: A 5 country web-based survey was conducted. MPs were defined 
as: unintentionally forgetting (UF) to take insulin, questioning whether or not 
insulin had been taken (QT), or questioning how much insulin dose was taken 
(QD). Data from Canadian respondents were analyzed and compared to the other 
countries (US, UK, Germany, and China). Results: A total of 350 respondents in 
Canada completed the survey (74.0% Type 1, 52.0% male, mean age of 37.1 years, 
mean age of diabetes onset of 24.2). The prevalence of MPs was 60.6% (UF), 76.3% 
(QT) and 44.6% (QD) in the past month with only approximately 1/3 being confi-
dent they knew what to do when having an MP. Between 21.5% (QT) and 37.4%(UF) 
tested their blood glucose and 32.6% (QD) – 51.6% (QT) skipped their insulin dose 
and waited for next scheduled dose when experiencing a MP, requiring, on aver-
age, between 8.5 (QT)–19.1 (UF) hours for return to normal blood glucose ranges. 
Patients conducted between 1.9 (QT) –5.0 (UF) extra BG monitoring tests the week 
following the MP and reported moderate negative impacts on their ability to 
work, physical and emotional functioning. Up to 13.7% missed a work day (UF) 
and between 10.8% (QT) and 16.8% (UF) visited their health care provider as a 
result of MP Compared to respondents in the other countries (N= 1404), Canadian 
respondents were reported significantly longer recovery times for returning to 
normal blood glucose levels following a MP and were significantly more likely 
to experience hyperglycemia following UF/QD than patients in other countries 
(p< .05). cOnclusiOns: These findings suggest that MPs have economic implica-
tions, impact patients’ functioning and well-being and may be serious obstacles 
to optimal diabetes control.
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Objectives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. The purpose of this study 
was to examine these impacts in the UK and compare these findings to data 
from US, Germany, Canada, and China). MethOds: A 5 country web-based survey 
examining MPs was conducted. MPs were defined as: unintentionally forgetting 
(UF) to take insulin, questioning whether or not insulin had been taken (QT), or 
questioning amount of insulin dose (QD). Results: A total of 350 UK respondents 
(52.0% Type 1), 49.1% male, mean age of 40.3, mean age of diabetes onset of 25.5 
completed the survey. The prevalence of MPs was 66.6% (UF) forgetting, 84.9% (QT) 
56.9% (QD). MPs occurred most frequently when relaxing or doing household jobs. 
Between 13.7% (UF) – 32.6% (QT) of respondents skipped their insulin dose due 
to a MP and required between 1.4 (QD)–13.1 (UF) hours, on average, to return to 
normal blood glucose range. As a result of a MP, patients conducted between 1.7 
(QT) –6.8 (UF) extra BG monitoring tests , reported a moderate negative impact on 
their physical and emotional functioning, as well as their ability to go to or func-
tion optimally at work and between 8.1% (QT) and 20.0% (UF) visited/contacted 
their health care provider . Economic implications include cost of additional BG 
strips, lost work productivity and health care resource utilization. Compared to 
respondents in the US, Germany, China and Canada (N= 1404), UK respondents 
conducted significantly more BG tests during the week following a missed dose 
of insulin were more likely to take a dose of insulin following a MP without test-
ing their BG. cOnclusiOns: These findings suggest that MPs in the UK carry 
financial burden, impact patients’ daily functioning and well-being and may be 
serious obstacles to optimal diabetes control.
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comPLiance? a stuDy BaseD on french ims LifeLinK Disease anaLyzer 
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Grandfils N., Le Jeunne P., Maillard C., Solomiac A., Besson A.
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Objectives: To compare antidiabetic treatment compliance with regards to the 
fixed or free treatments combination. MethOds: A retrospective study based on 
the IMS LifeLinkTM Diabetes Cohort linked to IMS Disease Analyzer, a longitudinal 
patient database containing the electronic health records of patients followed-up 
by a representative panel of French general practitioners. Two cohorts of patients 
treated both with metformin and DPPIV were constituted, the first one treated with 
fixed associations (“fixed cohort”), the second one treated with free associations 
(“free cohort”). Study investigated patients’ demographic and clinical character-
istics, conditions of use, persistence rates, medication possession ratio (MPR) and 
proportion of days covered (PDC) of the two cohorts. Results: Respectively 2 234 
and 8220 patients have been treated with free and fixed antidiabetic associations 
between 2007 and 2013. Patients are significantly older (66 vs. 64 years, p< 0.01) in 
the free cohort where the proportion of men is significantly lower (56% vs. 63%, 
p< 0.0001). Nevertheless diabetes oldness is the same (about 10 years) in both 
system structure and in cost transparency, the cost estimation methodology varied 
among countries. One limitation of this study is that diagnostic related group (DRG) 
tariffs were used to estimate several costs, which may not accurately represent the 
burden of a specific complication nor take into account the full burden of follow-up 
after an acute event.
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Objectives: To assess the direct medical costs for aggressive limb preservation 
treatment of diabetic foot ulcer (DFU) in a highly-specialized hospital setting in 
Russia MethOds: A retrospective data analysis of 156 admissions during 1-year 
period was done to get direct costs (associated with hospital stay, conservative 
and surgical treatment and laboratory testing) for treatment of DFU in a highly-
specialized inpatient department in Russian setting (Federal Endocrinology 
Centre). Results: The median cost of hospital treatment was 2270 EUR and 
increased with severity level, defined according to Wagner classification, ranging 
from 1590 EUR (grades 0-2) to 3812 EUR (grade 3) and 7683 EUR (grade 4), the differ-
ence was statistically significant. The length of stay in a hospital also correlated 
with the severity level starting with 14 days for grade 1 and reaching 39 days for 
grade 4. The costs of treatment were significantly higher for patients with inad-
equate vascular status requiring surgery – the median was 6185 EUR for cases with 
only angioplastic surgery and 8622 EUR for cases with both angioplastic and foot 
surgery provided. cOnclusiOns: Treatment of DFU aimed at limb preservation is 
resource consuming, costs for treating severe stage ulcer are 4,8 times higher than 
are those for treating low-stage ulcer. The high costs of treating severe stages of 
DFU in a specialized hospital setting emphasize the value of intensive outpatient 
interventions designed to prevent ulcer progression.
DiaBetes/enDocrine DisorDers – Patient-reported outcomes &  
Patient Preference studies
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risK factors for Discontinuation of insuLin PumP theraPy in 
PeDiatric anD young aDuLt Patient grouPs
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Objectives: Previous studies have shown that only a small number of pediatric and 
young adult patients discontinue pump therapy, but risk factors for discontinuation 
are unclear. Aim of this study was to identify characteristics of pediatric and young 
adult patients with pump therapy which are associated with discontinuation of 
treatment. MethOds: Retrospective cohort study using a representative nation-
wide database (LRx; IMS Health) in Germany covering > 80% of all prescriptions to 
members of statutory health insurances in 2008-2011. All patients (age groups: < 6, 
6-< 12, 12-< 18, 18-< 25 years) with new prescriptions of insulin pumps or related 
material were identified (2009-2011) and were followed for ≥ 12 months. Results: 
Overall, 3057 new pump users were identified, of whom 177 (5.8%) switched to other 
forms of insulin therapy within 12 months. Discontinuation was lowest in the age 
group < 6 years (2.1%) and was highest in adolescents (12-< 18 years: 7.5%) (p< 0.01). 
In age-adjusted logistic regression, usage of steel needles (Odds ratio, OR, 95%CI: 
1.69; 1.20-2.44) and prescriptions of antiepileptics (3.14; 1.49-6.59) were related to 
pump discontinuation. In younger age groups only, discontinuation was signifi-
cantly higher in patients with thyroid therapy as a surrogate measure for thyroid 
autoimmunity (< 6 years: 14.3%; 6-< 12 years: 25.0%) (p< 0.01). cOnclusiOns: About 
94% of pediatric and young adult patients maintained insulin pump therapy within 
12 months. Adolescence (12-18 years), usage of steel needles and prescriptions of 
antiepiletic drugs are independent predictors of discontinuation. In younger age 
groups (< 12 years) also thyroid therapy (indicating autoimmunity) was related to a 
higher risk of discontinuation.
PDB74
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Objectives: To describe persistence patterns to OHM in newly treated Irish patients 
with T2DM. The study also investigated the effect of age, gender, reimbursement 
scheme and type of OHM on persistence. MethOds: A population based retrospec-
tive cohort study was conducted using national pharmacy claims databases, includ-
ing two community drugs schemes; Long Term Illness, (LTI, non-means tested) and 
General Medical Services (GMS, means tested). Newly treated T2DM patients were 
identified for 2008-2009, having received no OHM in the previous year, and followed 
up until Nov-2012. Patients who subsequently switched or received additional OHM 
were excluded. Non-persistence was defined as a prescription gap of > 12 weeks 
and within 1 year of initiating treatment. Logistic regression examined associations 
of age, gender, scheme and type of OHM with persistence with results presented 
as odds ratios (OR) and 95% confidence intervals (CI). Results: A total of 15,174 
persons were eligible for the study. Most patients were initiated on metformin 
(79.4%) and sulphonylureas (19.1%). Persistence at 1 year was 60.9%. The median 
overall time to non-persistence was 51.5 days. Men were slightly more likely to 
be persistent than women (OR= 1.08; 95%CI= 1.001 to1.15; p= 0.0025). Patients aged 
16-44 and 75+ were less likely to be persistent than patients aged 55-64 (OR= 0.18; 
95%CI= 0.16-0.21; p< 0.0001 and OR= 0.67; 95%CI= 0.60-0.75; p< 0.0001 respectively). 
Patients registered with the LTI Scheme were more likely to be persistent than 
from the GMS Scheme (OR= 1.35; 95%CI= 1.20-1.51; p< 0.0001). Patients initiated on 
